# Imatinib for Multiple Sclerosis (MS) Relapses

> **NCT03674099** · PHASE2 · UNKNOWN · sponsor: **Tomas Olsson** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT03674099
- **Lead sponsor:** Tomas Olsson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-07-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674099, "Imatinib for Multiple Sclerosis (MS) Relapses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03674099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*